STAAR Surgical - STAA Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STAA shares.
View STAA analyst ratings or view top-rated stocks.

10 equities research analysts have issued 12 month price objectives for STAAR Surgical's stock. Their STAA share price forecasts range from $60.00 to $125.00. On average, they predict the company's share price to reach $86.80 in the next twelve months. This suggests a possible upside of 20.7% from the stock's current price.
View analysts price targets for STAA or view top-rated stocks among Wall Street analysts.

STAAR Surgical's stock was trading at $48.54 at the start of the year. Since then, STAA stock has increased by 48.1% and is now trading at $71.90.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our STAA earnings forecast.

STAAR Surgical (NASDAQ:STAA) released its earnings results on Wednesday, November, 2nd. The medical instruments supplier reported $0.25 EPS for the quarter, topping the consensus estimate of $0.13 by $0.12. The medical instruments supplier earned $76.05 million during the quarter, compared to analysts' expectations of $74.95 million. STAAR Surgical had a trailing twelve-month return on equity of 15.13% and a net margin of 13.54%. The firm's revenue was up 30.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.13 earnings per share.

STAAR Surgical updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $284.00 million-$284.00 million, compared to the consensus revenue estimate of $285.35 million.

6 employees have rated STAAR Surgical Chief Executive Officer Caren Mason on Glassdoor.com. Caren Mason has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

STAAR Surgical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (10.87%), Defender Capital LLC. (1.04%), APEIRON CAPITAL Ltd (0.70%), Ziegler Capital Management LLC (0.24%), Rice Hall James & Associates LLC (0.15%) and Waypoint Capital Advisors LLC (0.10%). Insiders that own company stock include Broadwood Partners, LP, Caren L Mason, Graydon C Hansen, Hans-Martin Blickensdoerfer, James E Francese, Jon K Hayashida, Keith Holliday, Patrick F Williams and Samuel J Gesten.
View institutional ownership trends.

Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STAA stock can currently be purchased for approximately $71.90.

STAAR Surgical (NASDAQ:STAA) has a market capitalization of $3.47 billion and generates $230.47 million in revenue each year. The medical instruments supplier earns $24.50 million in net income (profit) each year or $0.76 on an earnings per share basis.

The company employs 692 workers across the globe.

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The official website for the company is www.staar.com. The medical instruments supplier can be reached via phone at (626) 303-7902, via email at bmoore@staar.com, or via fax at 626-303-2962.